

Peter Naredi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5101527/publications.pdf>

Version: 2024-02-01

135
papers

4,517
citations

126858

33
h-index

118793

62
g-index

138
all docs

138
docs citations

138
times ranked

6576
citing authors

#	ARTICLE	IF	CITATIONS
1	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>Radiotherapy and Oncology</i> , 2022, 169, 114-123.	0.3	9
2	High expression of p62/SQSTM1 predicts shorter survival for patients with pancreatic cancer. <i>BMC Cancer</i> , 2022, 22, 347.	1.1	3
3	C-reactive protein identifies patients at risk of postpancreatectomy hemorrhage. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1949-1959.	0.8	1
4	Impact of patient, primary tumor and metastatic pattern including tumor location on survival in patients undergoing ablation or resection for colorectal liver metastases: A population-based national cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 375-383.	0.5	17
5	Survival and prognostic factors after transplantation, resection and ablation in a national cohort of early hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 394-403.	0.1	8
6	Alternative redox forms of ASNA-1 separate insulin signaling from tail-anchored protein targeting and cisplatin resistance in <i>C. elegans</i> . <i>Scientific Reports</i> , 2021, 11, 8678.	1.6	5
7	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	0.6	22
8	Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 619-631.	1.1	13
9	Patterns and resectability of colorectal cancer recurrences: outcome study within the COLOFOL trial. <i>BJS Open</i> , 2021, 5, .	0.7	10
10	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	4
11	ENPL-1, the <i>Caenorhabditis elegans</i> homolog of GRP94, promotes insulin secretion via regulation of proinsulin processing and maturation. <i>Development (Cambridge)</i> , 2020, 147, .	1.2	3
12	Presence of tumor-infiltrating CD8 ⁺ T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis. <i>Oncolmmunology</i> , 2020, 9, 1854519.	2.1	15
13	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	0.9	111
14	Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis. <i>Oncolmmunology</i> , 2020, 9, 1684126.	2.1	7
15	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102861.	2.0	29
16	Influence of primary tumour and patient factors on survival in patients undergoing curative resection and treatment for liver metastases from colorectal cancer. <i>BJS Open</i> , 2020, 4, 118-132.	0.7	15
17	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. <i>Lancet Oncology, The</i> , 2019, 20, 1482-1485.	5.1	2
18	EGFR, but not COX ² , protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. <i>Oncology Letters</i> , 2019, 17, 5361-5368.	0.8	9

#	ARTICLE	IF	CITATIONS
19	A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. <i>BMC Cancer</i> , 2019, 19, 568.	1.1	19
20	Prognostic factors for survival in stage IV rectal cancer: A Swedish nationwide case-control study. <i>Surgical Oncology</i> , 2019, 29, 102-106.	0.8	14
21	Centers of excellence or excellence networks: The surgical challenge and quality issues in rare cancers. <i>European Journal of Surgical Oncology</i> , 2019, 45, 19-21.	0.5	18
22	ECCO essential requirements for quality cancer care: Melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 164-178.	2.0	41
23	ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 179-193.	2.0	57
24	Diagnostic profile characteristics of cancer patients with frequent consultations in primary care before diagnosis: a case-control study. <i>Family Practice</i> , 2018, 35, 559-566.	0.8	2
25	Fractional uptake of circulating tumor cells into liver-lung compartments during curative resection of periampullary cancer. <i>Oncology Letters</i> , 2018, 16, 6331-6338.	0.8	9
26	Toward a Consensus on Centralization in Surgery. <i>Annals of Surgery</i> , 2018, 268, 712-724.	2.1	187
27	Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 976-983.	0.6	4
28	Clinical features of patients with non-metastatic lung cancer in primary care: a case-control study. <i>BJGP Open</i> , 2018, 2, bjpgopen18X101397.	0.9	4
29	ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 94-105.	2.0	94
30	ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 81-93.	2.0	54
31	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	5.1	153
32	Multidisciplinary training of cancer specialists in Europe. <i>European Journal of Cancer</i> , 2017, 83, 1-8.	1.3	24
33	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	1.3	25
34	Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure. <i>Pancreas</i> , 2016, 45, 900-907.	0.5	2
35	Present and future role of surgery in metastatic gastrointestinal malignancies. <i>Current Opinion in Oncology</i> , 2016, 28, 348-352.	1.1	0
36	Identification of patients with non-metastatic colorectal cancer in primary care: a case-control study. <i>British Journal of General Practice</i> , 2016, 66, e880-e886.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Increased consultation frequency in primary care, a risk marker for cancer: a case-control study. <i>Scandinavian Journal of Primary Health Care</i> , 2016, 34, 205-212.	0.6	25
38	Circulating Carnosine Dipeptidase 1 Associates with Weight Loss and Poor Prognosis in Gastrointestinal Cancer. <i>PLoS ONE</i> , 2015, 10, e0123566.	1.1	25
39	Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. <i>Cancer Biomarkers</i> , 2015, 15, 1-10.	0.8	22
40	Protection Against Cold in Prehospital Care: Wet Clothing Removal or Addition of a Vapor Barrier. <i>Wilderness and Environmental Medicine</i> , 2015, 26, 11-20.	0.4	29
41	The future of trials in surgical oncology. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 425-431.	12.5	29
42	Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement. <i>Tumor Biology</i> , 2015, 36, 9839-9847.	0.8	21
43	Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men. <i>British Journal of Dermatology</i> , 2015, 172, 700-706.	1.4	33
44	Asn1/TRC40 controls beta cell function and ER homeostasis by ensuring retrograde transport. <i>Diabetes</i> , 2015, 65, db150699.	0.3	25
45	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	1.3	349
46	Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012. <i>European Journal of Surgical Oncology</i> , 2014, 40, 454-468.	0.5	59
47	Later Stage at Diagnosis and Worse Survival in Cutaneous Malignant Melanoma Among Men Living Alone: A Nationwide Population-Based Study From Sweden. <i>Journal of Clinical Oncology</i> , 2014, 32, 1356-1364.	0.8	40
48	Validity and reliability of the Cold Discomfort Scale: a subjective judgement scale for the assessment of patient thermal state in a cold environment. <i>Journal of Clinical Monitoring and Computing</i> , 2014, 28, 287-291.	0.7	24
49	Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma. <i>International Journal of Oncology</i> , 2014, 44, 99-104.	1.4	25
50	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. <i>Oncotarget</i> , 2014, 5, 9609-9618.	0.8	62
51	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	1.3	76
52	Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. <i>British Journal of Dermatology</i> , 2013, 168, 779-786.	1.4	40
53	Non-invasive identification of melanoma with near-infrared and skin impedance spectroscopy. <i>Skin Research and Technology</i> , 2013, 19, e473-8.	0.8	12
54	Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden. <i>European Journal of Cancer</i> , 2013, 49, 2705-2716.	1.3	55

#	ARTICLE	IF	CITATIONS
55	Depletion of the ER chaperone ENPL-1 sensitizes <i>C. elegans</i> to the anticancer drug cisplatin. <i>Worm</i> , 2013, 2, e24059.	1.0	15
56	Interaction between the Anticancer Drug Cisplatin and the Copper Chaperone Atox1 in Human Melanoma Cells. <i>Protein and Peptide Letters</i> , 2013, 21, 63-68.	0.4	19
57	Protection against Cold in Prehospital Care: Evaporative Heat Loss Reduction by Wet Clothing Removal or the Addition of a Vapor Barrier—A Thermal Manikin Study. <i>Prehospital and Disaster Medicine</i> , 2012, 27, 53-58.	0.7	34
58	NIR and skin impedance spectroscopic measurements for studying the effect of coffee and alcohol on skin, and dysplastic naevi. <i>Skin Research and Technology</i> , 2012, 18, 486-494.	0.8	1
59	A Directed RNAi Screen Based on Larval Growth Arrest Reveals New Modifiers of <i>C. elegans</i> Insulin Signaling. <i>PLoS ONE</i> , 2012, 7, e34507.	1.1	13
60	Liver-metastatic potential of colorectal cancer is related to the stromal composition of the tumour. <i>Anticancer Research</i> , 2012, 32, 5183-91.	0.5	26
61	Type IV collagen as a tumour marker for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2011, 37, 611-617.	0.5	33
62	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	5.1	571
63	Mitochondrial Function Is Required for Secretion of DAF-28/Insulin in <i>C. elegans</i> . <i>PLoS ONE</i> , 2011, 6, e14507.	1.1	21
64	In vivo skin measurements with a novel probe head for simultaneous skin impedance and near-infrared spectroscopy. <i>Skin Research and Technology</i> , 2011, 17, 494-504.	0.8	9
65	The effect of active warming in prehospital trauma care during road and air ambulance transportation - a clinical randomized trial. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2011, 19, 59.	1.1	74
66	Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6951-6956.	3.3	94
67	Better value cancer care for the 21st century. <i>Annals of Oncology</i> , 2011, 22, 2541-2545.	0.6	1
68	Evaluation of cell lysis methods for platinum metallomic studies of human malignant cells. <i>Analytical Biochemistry</i> , 2010, 396, 76-82.	1.1	33
69	ASNA-1 Activity Modulates Sensitivity to Cisplatin. <i>Cancer Research</i> , 2010, 70, 10321-10328.	0.4	26
70	Increased sensitivity to platinating agents and arsenite in human ovarian cancer by downregulation of ASNA1. <i>Oncology Reports</i> , 2009, 22, 869-75.	1.2	14
71	ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 491-499.	1.1	20
72	Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. <i>British Journal of Cancer</i> , 2009, 101, 91-97.	2.9	85

#	ARTICLE	IF	CITATIONS
73	Atypical Liver Resections of Colorectal Metastases. , 2009, , 141-147.		0
74	Characterization of healthy skin using near infrared spectroscopy and skin impedance. Medical and Biological Engineering and Computing, 2008, 46, 985-995.	1.6	28
75	Expression pattern and circulating levels of endostatin in patients with pancreas cancer. International Journal of Cancer, 2008, 122, 2805-2810.	2.3	39
76	Databases of hepatic resection for metastatic colorectal cancerâ€”useful aids for clinical decision-making. Surgical Oncology, 2008, 17, 15-16.	0.8	1
77	Why do we need a core curriculum in surgical oncology in Europe?. Surgical Oncology, 2008, 17, 267-269.	0.8	6
78	Recommended core curriculum for the specialist training in surgical oncology within Europe. Surgical Oncology, 2008, 17, 271-275.	0.8	10
79	Hydrophilic interaction liquid chromatography (HILIC) coupled to inductively coupled plasma mass spectrometry (ICPMS) utilizing a mobile phase with a low-volatile organic modifier for the determination of cisplatin, and its monohydrolyzed metabolite. Journal of Analytical Atomic Spectrometry, 2008, 23, 948.	1.6	29
80	Sentinel node biopsy in malignant melanoma: Swedish experiences 1997â€”2005. Acta OncolÃ³gica, 2008, 47, 1519-1525.	0.8	19
81	Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-Î±2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Annals of Oncology, 2007, 18, 1691-1697.	0.6	34
82	ASNA-1 Positively Regulates Insulin Secretion in C. elegans and Mammalian Cells. Cell, 2007, 128, 577-587.	13.5	109
83	Determination of platinum in human subcellular microsomes by inductively coupled plasma mass spectrometry. Analytical Biochemistry, 2007, 363, 135-142.	1.1	17
84	Expression of the Human Copper Influx Transporter 1 in Normal and Malignant Human Tissues. Journal of Histochemistry and Cytochemistry, 2006, 54, 1041-1049.	1.3	55
85	Isolated hyperthermic liver perfusion with cytostatic-containing perfusate activates the complement cascade. British Journal of Surgery, 2005, 79, 948-951.	0.1	11
86	Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 603-609.	1.1	9
87	Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunology, Immunotherapy, 2004, 53, 840-1.	2.0	14
88	Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the ¹³³ Xe-clearance technique. Cancer Chemotherapy and Pharmacology, 2004, 54, 213-8.	1.1	0
89	Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Anticancer Research, 2004, 24, 1837-42.	0.5	9
90	Treatment of primary liver cancer. The European Journal of Surgery, 2003, 164, 569-574.	1.0	6

#	ARTICLE	IF	CITATIONS
91	The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. <i>Supportive Care in Cancer</i> , 2003, 11, 304-312.	1.0	16
92	A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2003, 29, 459-466.	0.5	10
93	Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma. <i>Melanoma Research</i> , 2003, 13, 307-311.	0.6	8
94	Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. <i>Anticancer Research</i> , 2003, 23, 537-42.	0.5	10
95	Interleukin-2 and Histamine Dihydrochloride in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3558-3559.	0.8	7
96	Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. <i>British Journal of Cancer</i> , 2002, 87, 194-201.	2.9	50
97	Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon- γ in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. <i>Annals of Oncology</i> , 2002, 13, 441-449.	0.6	20
98	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 125-133.	0.8	118
99	Pharmacokinetics of Histamine Dihydrochloride in Healthy Volunteers and Cancer Patients: Implications for Combined Immunotherapy with Interleukin-2. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 774-781.	1.0	11
100	Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration in the rat. <i>Life Sciences</i> , 2002, 70, 969-976.	2.0	7
101	Results From a Randomized Phase III Study Comparing Combined Treatment With Histamine Dihydrochloride Plus Interleukin-2 Versus Interleukin-2 Alone in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 125-133.	0.8	130
102	Histamine as an adjunct to immunotherapy. <i>Seminars in Oncology</i> , 2002, 29, 31-34.	0.8	9
103	Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. <i>European Journal of Surgical Oncology</i> , 2001, 27, 477-481.	0.5	8
104	P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. <i>Cancer</i> , 2001, 91, 727-736.	2.0	28
105	Alleviating oxidative stress in cancer immunotherapy: a role for histamine?. <i>Medical Oncology</i> , 2000, 17, 258-269.	1.2	18
106	Histamine: A Novel Approach to Cancer Immunotherapy. <i>Cancer Investigation</i> , 2000, 18, 347-355.	0.6	44
107	Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1135-1144.	0.5	81
108	Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. <i>European Journal of Surgical Oncology</i> , 1999, 25, 179-185.	0.5	43

#	ARTICLE	IF	CITATIONS
109	Validation of the internal reference technique for microdialysis measurements of interstitial histamine in the rat. <i>Life Sciences</i> , 1999, 65, 1765-1771.	2.0	11
110	Dual cytoplasmic and nuclear distribution of the novel arsenite-stimulated human ATPase (hASNA-I). <i>Journal of Cellular Biochemistry</i> , 1998, 71, 1-10.	1.2	11
111	Histamine and Cytokine Therapy: Paper presented at the annual meeting of the Swedish Oncology Society, Stockholm, 1997. <i>Acta OncolÅ³gica</i> , 1998, 37, 347-353.	0.8	30
112	Immunohistochemical Analysis of the Distribution of the Human ATPase (hASNA-I) in Normal Tissues and Its Overexpression in Breast Adenomas and Carcinomas. <i>Journal of Histochemistry and Cytochemistry</i> , 1998, 46, 1243-1248.	1.3	10
113	Isolated Hepatic Perfusion with Extracorporeal Oxygenation Using Hyperthermia TNF± and Melphalan: Swedish Experience. <i>Recent Results in Cancer Research</i> , 1998, 147, 120-126.	1.8	26
114	Synergy between cisplatin and an inhibitor of S-adenosylmethionine dependent transmethylation in human ovarian adenocarcinoma cells. <i>International Journal of Oncology</i> , 1997, 11, 869-74.	1.4	1
115	Histamine in cancer immunotherapy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 193-202.	0.6	30
116	Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 444-448.	1.1	4
117	Isolation of the ATP-Binding Human Homolog of thearsAComponent of the Bacterial Arsenite Transporter. <i>Genomics</i> , 1996, 36, 486-491.	1.3	34
118	Histamine, cimetidine and colorectal cancer. <i>Nature Medicine</i> , 1996, 2, 364-364.	15.2	8
119	Membrane Transport of Platinum Compounds. , 1996, , 91-105.		0
120	Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. <i>Clinical Cancer Research</i> , 1996, 2, 311-7.	3.2	12
121	Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth. <i>International Journal of Cancer</i> , 1995, 63, 592-596.	2.3	6
122	Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.. <i>Journal of Clinical Investigation</i> , 1995, 95, 1193-1198.	3.9	42
123	Hepatic artery occlusion and energy charge in rat liver tumour. <i>Annals of Oncology</i> , 1994, 5, 961-963.	0.6	0
124	Histamine in immunotherapy of advanced melanoma: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 416-419.	2.0	58
125	Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial. <i>Cancer</i> , 1994, 74, 2749-2756.	2.0	33
126	Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. <i>Surgical Oncology</i> , 1994, 3, 103-108.	0.8	70

#	ARTICLE	IF	CITATIONS
127	Quantitative measurements of collateral arterial blood flow in nonarterialized rat liver grafts. <i>Transplant International</i> , 1994, 7, 136-139.	0.8	7
128	Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. <i>Cancer Research</i> , 1994, 54, 6464-8.	0.4	22
129	Whole body energy expenditure protein breakdown and polyamine excretion during high dose treatment with interleukin-2 and interferon-alpha. <i>The European Journal of Surgery</i> , 1994, 160, 67-75.	1.0	2
130	Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. <i>Surgical Oncology</i> , 1993, 2, 105-112.	0.8	11
131	The influence of hepatic artery ligation and of vasopressin on liver tumour blood flow in rats. <i>Journal of Surgical Oncology</i> , 1992, 50, 70-76.	0.8	5
132	Cytotoxicity of liver macrophages against liver tumours. Influence of betamethasone, indomethacin and allopurinol. <i>Anticancer Research</i> , 1991, 11, 1827-30.	0.5	2
133	Aggregation of microspheres in blood flow measurements. <i>International Journal of Microcirculation, Clinical and Experimental</i> , 1991, 10, 169-80.	0.6	2
134	Evaluation of blood flow measurements with microspheres and rubidium--an experimental study in rats. <i>International Journal of Microcirculation, Clinical and Experimental</i> , 1990, 9, 423-37.	0.6	4
135	Techniques for measuring regional blood flow. <i>International Journal of Radiation Oncology Biology Physics</i> , 1987, 13, 945-946.	0.4	2